قالب وردپرس درنا توس
Home / Health / Cheap Combi Pill Cuts Heart, Stroke Risks, Study Results – St George News

Cheap Combi Pill Cuts Heart, Stroke Risks, Study Results – St George News



  Pharmacy

Associated Press Photo by Ebrahim Noroozi, St. George News

LONDON (AP) ̵

1; A cheap daily pill that combines four drugs reduces the risk of heart attacks, strokes and heart failure in a large study , which suggests that it may be a good way to prevent heart problems, especially in poor countries.

The pills contained two blood pressure medicines, a cholesterol drug and aspirin. Many people can not afford to take so many medicines individually or do not stick to it, so doctors believe a polyp may help. A previous study in India has found that it lowers cholesterol and blood pressure. The new study is much larger and provides more meaningful evidence as it tracks heart attacks, strokes, and other problems, not just risk factors.

About 6,800 people in Iran aged 50 to 75 were involved, some with previous heart problems, others without you. All received advice on a healthy lifestyle and half received polypillen. After five years, 6% of people in the pill group had a heart attack, stroke, or heart failure compared to 9% of the others. This resulted in a 34% lower risk for the polyp and a 22% lower risk after researchers considered other heart medications taken by the participants.

People who took the polypilla with great care in at least 70% of the cases

The main benefit seemed to be the reduction in cholesterol levels. The blood pressure did not change significantly. The side effects were similar in both groups. Some who developed cough while taking the polyp were switched to another version that replaced one of the four drugs. All medications are now cheap generic.

The findings were released Thursday in the British journal Lancet. The study was funded by the Tehran University of Medical Sciences, a foundation, and Alborz Darou, the company that makes the polypillen.

"This is an important step in the right direction," Dr. Salim Yusuf from McMaster University in Canada, who is conducting another polyp study, which is expected to be completed next summer. " This could be used in any reasonable country where we want to save lives ."

A study leader, Dr. med. Tom Marshall of the University of Birmingham, UK, said the results show that the polypilvate is a "viable" strategy for preventing heart disease in developing countries.

"It's much easier to give people a drug that works simultaneously with one However, Marshall said that this would be beneficial for people who already have access to good health care.

"But if you are in one This is a significant advantage "he said.

Dr Amit Khera, director of preventive cardiology at Southwestern Medical School in Texas, who plays no part in the Study, said he expects that polypills would have a wider application in the next few years, even if they would act in groups other than Central Asia descent tested in the Lancet study.

"Biology varies in different populations. So, before we apply it across India or all of North Africa, we need to know that these polypillas are actually safe in these populations, "he said.

Written by MARIA CHENG, Associated Press Medical Writer.

The Department of Health and Associated Press Science is sponsored by the Howard Hughes Medical Institute's Department of Science Education and is solely responsible for the content of the AP.

Copyright 2019 The Associated Press, All Rights Reserved, This material may not be published, transmitted, transcribed or


Source link